Tyra Biosciences’ (TYRA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a research report sent to investors on Monday,Benzinga reports. They currently have a $30.00 price objective on the stock.

A number of other research firms have also weighed in on TYRA. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Oppenheimer boosted their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Trading Up 5.0 %

Shares of Tyra Biosciences stock opened at $16.73 on Monday. The stock’s fifty day moving average price is $15.40 and its 200-day moving average price is $19.20. The firm has a market cap of $846.59 million, a P/E ratio of -10.39 and a beta of 1.04. Tyra Biosciences has a 12 month low of $12.17 and a 12 month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last issued its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $27.90, for a total transaction of $532,443.60. Following the completion of the sale, the chief executive officer now owns 1,355,927 shares of the company’s stock, valued at $37,830,363.30. The trade was a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Alan Fuhrman bought 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the transaction, the chief financial officer now owns 12,849 shares of the company’s stock, valued at $205,584. The trade was a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 58,731 shares of company stock worth $1,185,162 in the last three months. Corporate insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. HighVista Strategies LLC purchased a new position in shares of Tyra Biosciences during the second quarter worth $257,000. Franklin Resources Inc. purchased a new position in shares of Tyra Biosciences during the 3rd quarter valued at about $278,000. Valence8 US LP acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at about $310,000. SG Americas Securities LLC purchased a new stake in shares of Tyra Biosciences in the third quarter worth about $311,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Tyra Biosciences during the third quarter worth about $333,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.